Introduction
Australia and New Zealand have achieved very good control of community spread of SARS-CoV-2 during the global pandemic due to highly effective public health interventions.(1, 2) As of 20 January 2021, Australia had recorded 22,201 local cases with 909 total fatalities(3) and New Zealand had reported 1044 local cases with 25 fatalities.(4)The availability of effective vaccines offers an opportunity to consolidate this successful control and requires consideration of their application to key vulnerable populations including those with haematological disorders.
Haematological malignancies account for approximately 11% of all cancers in Australia and New Zealand.(5)Patients with lymphoid malignancies, including chronic lymphocytic leukaemia (CLL) and multiple myeloma, recipients of allogeneic stem cell transplantation and of potent B- and T-cell depleting therapies are particularly vulnerable to serious viral infections.(6-9) Haematology patients are often severely immune compromised due to their underlying disease and/or associated therapy, and experience higher rates of infection than age-matched controls.
For a copy of the full paper click here
COVID-19 Morbidity and Mortality Risk Factors in Haematology Patients
Adults with haematological malignancies are reported to be at high risk of progression to severe disease and death from COVID-19 with an estimated mortality of 36% or greater, comparable to the mortality rate of aged care residents.(10-13) While mortality risk in paediatric patients (estimated at 4%) is lower, it is much higher than in healthy children.(11)
Patients with haematological malignancies, including lymphoid disorders, multiple myeloma, acute myeloid leukaemia and myelodysplastic syndrome appear to be at highest risk of mortality.(10, 11) Among those with lymphoid malignancies who acquire COVID-19, hospitalisation rates are up to 90% and intensive care admission rates 35%.(14) CLL patients who had previously received immunochemotherapy have a mortality of up to 60%. In a multi-national cohort of patients with multiple myeloma and COVID-19 infection, the COVID-19-related mortality rate was 33% with geographical variation from 27-57% of hospitalised patients.(12) In a myelofibrosis population study, the COVID-19 mortality was 48% (15). Limited data suggest that chronic phase chronic myeloid leukaemia patients on tyrosine kinase inhibitors with COVID-19 have mortality rates comparable to the general population.(16),(17) In myelofibrosis additional risk factors of mortality include discontinuation of ruxolitinib at COVID-19 diagnosis, possibly due to rebound inflammation.(15)
Patients with benign haematological disorders have varying outcomes depending on the underlying disease and associated co-morbidities (18-21). Patients with sickle cell disease appear to be at particular risk with an age standardised mortality ratio of 7.7 times (20).
In patients with haematological malignancies, COVID-19-related mortality is not always related to recent therapy of the underlying malignancy (11, 12, 14). Risk factors for mortality include age >60 years, active or progressive disease, ECOG performance score ≥2, absolute lymphocyte count ≤0.6 x 109/L, platelet count ≤40 x 109/L, an elevated LDH, and a raised C-reactive protein.(10, 11) In multiple myeloma additional predictors of include high risk cytogenetics (del17p, t(4;14), amp 1q or t(14;16) and renal disease.(12, 22) Furthermore, patients with haematological malignancies who recover from COVID-19 display distinct, prolonged immunological complications compared to those with solid organ malignancies who have similar rates to the general population.(23)
Impaired SARS-CoV-2 Clearance and Viral Evolution in Patients with Haematological Malignancies
Patients with haematological malignancies are unable to clear certain viruses (14, 24). Preliminary reports suggest that these patients when exposed to SARS-CoV-2 display heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding more so than patients with solid organ malignancies(23, 25). Therefore, these patients have an ongoing risk of recurrent infection and of onward transmission. Furthermore, preliminary data suggests that immunecompromised patients have the potential for accelerated viral evolution (25, 26).
Vaccine Considerations
These data should inform future preventative efforts as Australia and New Zealand commence their vaccination campaigns. At time of writing there are two vaccines of relevance in Australia and New Zealand. The Pfizer/BioNTech SARS-Cov-2 vaccine is a first-in-class mRNA vaccine which in an international phase 3 study was administered to 43,448 participants aged 16 or older in a two dose regimen 21 days apart. The vaccine was 95% effective against symptomatic COVID-19 from seven days after the second dose. Efficacy was consistent across age, gender and ethnicity, and no serious safety concerns were reported. This trial included a small number of patients (n=76) with leukaemia or lymphoma as a co-morbidity, 36 of whom received the vaccine (27).
The AstraZeneca ChAdOx1 nCOV-19 vaccine is a replication-deficient chimpanzee adenoviral vectored vaccine given in a two dose regimen. In a pooled analysis across four studies with varying dosing, overall vaccine efficacy was 70.4% with no serious safety concerns reported.(28) In a subgroup of 8,895 participants who received two standard doses (as will be administered in practice), vaccine efficacy was 62%. Experience with viral vectored vaccines is limited with no evidence in haematology patients.
An alternative vaccine available internationally is the Moderna mRNA SARS-CoV-2 vaccine (mRNA-1273) which is another two dose regimen vaccine administered 28 days apart, shown in a phase 3 study to have an overall efficacy of 94%.(29) Other vaccines with potential future relevance in Australia and New Zealand include the Novovax vaccine NVX-CoV2373, the Janssen vaccine Ad26Cov2S and access to the COVAX facility.
None of these studies included immunocompromised patients, and we await studies to evaluate these vaccines specifically in haematology patients. Despite the lack of data, none of these are live vaccines and therefore pose no risk of COVID-19 transmission.
Recommendations
Acknowledging the paucity of prospective data, representative experts from the Haematology Society of Australia and New Zealand, have collaborated with Infectious disease specialists on this consensus position statement regarding COVID-19 vaccination in haematology patients in Australia and New Zealand. Broadly we consider that the following applies to all haematology patients: